Active-specific immunization against melanoma: is the problem at the receiving end?


Journal Article (Review)

The recent progress in tumor immunology is a striking example of the successful application of modern biotechnology to understand the complex phenomenon of immune-mediated cancer rejection. Tumor antigens were identified and successfully utilized in active immunization trials to induce tumor antigen-specific T cells. This achievement has left, however, clinicians and researchers perplexed by the paradoxical observation that immunization-induced T cells can recognize tumor cells in standard assays but cannot induce tumor regression. A closer look at T cell physiology and tumor biology suggests that this observation is not so surprising. Here, we argue that successful immunization is one of several steps required for tumor clearance while more needs to be understood about how T cells localize and are effective within a tumor microenvironment impervious to the execution of their effector function.

Full Text

Duke Authors

Cited Authors

  • Monsurrò, V; Wang, E; Panelli, MC; Nagorsen, D; Jin, P; Katia, Z; Smith, K; Ngalame, Y; Even, J; Marincola, FM

Published Date

  • December 2003

Published In

Volume / Issue

  • 13 / 6

Start / End Page

  • 473 - 480

PubMed ID

  • 15001166

Pubmed Central ID

  • 15001166

International Standard Serial Number (ISSN)

  • 1044-579X

Digital Object Identifier (DOI)

  • 10.1016/j.semcancer.2003.09.011


  • eng

Conference Location

  • England